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     One of the side effects of diabetes epidemic today in the world is painful neuropathy, the reasons and 
treatments of which are un- known. Due to the importance of the problem of pain treatment as one of the 
harmful phenomena in life, this research studies the effect of continued diabetes on the formalin induced 
pain and Baclofen analgesia in rats. Moreover, the effect of Baclofen as a non-opiate, analgesic drug on 
the increased pains in the quiescent phase as the model of diabetic pain is investigated. The method is 
experimental, evaluating the pain level through conducting the formalin test in 3 groups of rats. The first 
group was divided to control (injection normal saline) and diabetic (injection aloxan 100 mg/kg) which 
were tested, after one to four weeks from the beginning of diabetes, the second one was divided to a new 
control and diabetic group, and before performing formalin test, the Baclofen (10 mg/kg) was injected to 
them. And the third one was divided to two diabetic groups that received Baclofen and normal saline and 
then the pain of the quiescent phase was compared in them. The results indicate that diabetes increases 
formalin induced pain (P<0.05) and remained with continued diabetes. It also indicates that diabetes 
establishes increased pain in the quiescent phase (P<0.05), yet, it has had no influence on the Baclofen 
analgesic effect on the first phase of formalin test but increased it on the second phase. Moreover, 
Baclofen can quiet the increased pain in quiescent phase (P<0.05) very well.  Due to the results of this 
study it seems that diabetes, with the changes in the central and peripheral pathways of the pain and also 
pain control, increases the pain. More studies are required for determining its mechanisms. These changes 
are accompanied with weakening the internal anti pain systems such as Gaba ergic, which can be treated 
with Baclofen. Diabetes has no interaction with the Baclofen’s analgesic effect, so, Baclofen may be 
recommended as an effective drug to comfort painful diabetic Neuropathy. 
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INTRODUCTION 
     While conventional medical treatment of 
diabetes mellitus markedly prolongs life-span, 
serious medical complications affect a large 
proportion of more than 10 million people 
believed to have diabetes in the USA. Peripheral 
neuropathy is the most common complication, 
affecting one third of newly diagnosed cases. 
The frequency of neuropathy increases with 
duration of disease to affect over half of all 
diabetics. Nerve dysfunction usually progresses 
to become a distal symmetrical poly-neuropathy 
with morphologic evidence of paranodal 
widening, segmental demyelination and 
remyelination, axonal atrophy and ultimate fiber 
loss. This pathology is accompanied by loss of 
sensory function that, when coupled with 
impaired healing processes and vascular disease, 
can lead to gangrene and limb amputation 
[1].Pain as a phenomenon is the subject of study 
in many different researches On the other hand; 
relieving pain is an essential problem which 
causes to use many different drugs.  Diabetes, 
one of the epidemic human diseases in recent 
years, has major vicinity with pain of which our 
knowledge about their relationship is little to be 
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     Somatic neuropathies can have various 
causes, e.g. severing of the nerve due to 
amputation or accident, blood circulation 
disorder upon manifestation of arterial occlusive 
disease or diabetes mellitus [3].  Diabetes causes 
painful neuropathy; a disgustful clinically 
unsolved problem and scientists suggest variety 
of drugs to appease it such as 3 cycle 
antidepressant [4], yet, neuropathic pain caused 
by nerve degeneration resists to opiate or non 
steroid drugs.  
     The mechanism of neuropathic pain and other 
physiologic normal pains are different [5].  
Gabaergic System, a pain relief mechanism, 
produces inhibitory neurotransmitter in CNS. 
Baclofen, has excitatory synaptic effect on 
GABA receptors so used as an anti-nociseptive 
drug in the treatment of trigeminal neuralgia [6]. 
Baclofen essentially manages pain by central 
mechanism compared to diabetic neuropathy 
which acts peripherally [7]. It is also used as an 
anti-inflammatory drug [8]. Baclofen and 
GABA drugs affect pancreas in vivo to increase 
insulin of plasma to reduce blood glucose of 
diabetic rats [9]. Exogenic administration of 
GABA agonist reverses spinal nerve ligation-
induced hyperalgesia [10]. Baclofen is a 
GABA.sub.B receptor agonist that has been used 
in the United States since 1977 for alleviating 
the signs and symptoms of spasticity resulting 
from multiple sclerosis or spinal cord injury. 
The mechanism of action of Baclofen in 
spasticity appears to involve agonism at 
GABA.sub.B receptors of the spinal cord. 
Thermal hyperalgesia showed a reduced 
sensitivity to the anti-nociceptive effect of 
Baclofen (4 mg/kg i.p) [11],  Different  dosages 
of Baclofen show its antinociseptive controlling 
effect [12], the lower the dosage, the higher 
effect specially in locomotive disorders [13]. 
The analgesic effect of Baclofen is similar to 
morphine; with no    addictive effect [14, 27]. 
Low dose usage of Baclofen and Gabapentin 
dose not affect motor performance, but produced 
dose-dependent inhibition of both phases in 
Formalin test in mice [15]. Baclofen injection to 
VB complex of thalamus reduces transmission 
and modulation of noxious information [16]. 
GABAPENTIN and Baclofen inhibit both 
phases in FT in mice [17]. The inhibitory effects 
of gaba and Baclofen in trachea is greater than 
other tissues in diabetic and control rats [18]. 
     Recently, Gallop et al. have developed new 
     prodrugs of (R)-Baclofen and Baclofen 
analogs that are well absorbed in the large 
intestine/colon [19]. A formalin assessment test 
is performed according to the procedure 
described in literature [20] Formalin Test is a 
well validated model and serves as a model of 
neuropathic pain behavior in rats. It is an 
effective prescreening test of molecules and may 
facilitate drug targeting [21]. Alternative animal 
models of neuropathic pain conditions may 
involve selection of an animal that naturally 
possesses a painful disease condition providing 
neuropathic pain and its symptoms such as HIV 
or Herpes or cancer or diabetes. Animals may be 
modified to possess a pain condition due to a 
disease in a variety of ways for example by 
administration of Streptozocin to induce a 
diabetic neuropathy [22]. The effect of FT 
(Formalin Test) in diabetic and normal rats as a 
pain inducer and the anti-analgesic function of 
Baclofen as a pain reliever is studied in this 
article to find out Baclofen behavioral and 
functional effects in different phases of FT in 
diabetic rats. 
 
MATERALS AND METHODS 
     The method is experimental by evaluating the 
pain level through conducting the formalin test 
in 3 groups of rats (70 rats, NMRI). The first 
group was divided to control (injection normal 
saline) and diabetic (injection aloxan 100mg/kg) 
subgroups which following the observation of 
the routine signals of diabetes, after one to four 
weeks from the beginning of diabetes were 
tested. The second group was divided to the 
control and diabetic subgroups, which before 
performing formalin test; the Baclofen (10 
mg/kg) was injected to the previous subgroup. 
And the third group was divided to two diabetic 
subgroups that received Baclofen and normal 
saline, after which the pain of the quiescent 
phase was compared between them. 
     Formalin Test: After the injection of 50µlit 
formalin %2.5 (IC) into the right claw foot of 
the rat, the animal was put into a plaxi glass 
room (29, 29.30 cm) on a glass with a mirror 
under it. The animal’s pain behavior was divided 
into 4 positions and we scored them between 0 
to 3; then the pain observed in 60 minutes, the 
time between (0–5) as phase one, the time 
between (6–15) as quiescent phase and the time 
between (16–60) as phase two, were determined 
[20].  
 Diabetes creation and blood glucose 
Journal of Paramedical Sciences (JPS)                          Spring 2010 Vol.1, No.2 ISSN 2008-496X 
______________________________________________________________________________________________________________________________________________________________________________________________ 
     
 
14 
concentration measurement: Diabetes creation 
was done with injection of alloxan monohydrate 
(100 mg/kg), (IC) over the neck and 7 days after 
that, the blood glucose was measured with 
orthotoloiden method, after one to four weeks 
from the beginning of diabetes, and the formalin 
test was conducted. 
   Analgesia creation: Baclofen (10 mg/kg) 
injection (IP) was performed 15 minutes before 
the formalin injection. 
Drugs:Alloxan (sigma Co)-Baclofen (sigma Co). 
 
Statistical analysis 
   For comparing pain due to formalin in the 5 
groups at each of the three phases, 3 one-way 
ANOVA tests, and for multiple comparisons 
Tukey HSD method were used. To compare the 
rate of pain decrease due to Baclofen in the 5 
groups at each of the three phases, 3 one-way 
ANOVA tests, and for multiple comparisons 
Tukey HSD method were utilized. For 
comparing quiescent phase pain in each of salin 
and Baclofen groups at week 1 and 4, two 
independent sample t-tests were used. 
 
RESULTS 
   1- Diabetes effects on the formalin induced 
pain: it significantly increases the formalin 
induced pain   (P<0.05) (figure1). With 
diabetes continued (1-4 weeks), the formalin 
induced pain continues and there are no 
significant differences in the same period. 
Diabetes also, created formalin induced pain in 
quiescent phase (6-15 min) that was significant 
in the first week of diabetes (figure 1). 
   2- The effect of diabetes on Baclofen 
analgesia: diabetes didn’t create significant 
differences in Baclofen analgesia in the first 
phase of formalin test (figure 2). Also, diabetes 
increased Baclofen analgesia in the second 
phase and in 2 weeks it was significant (P< 0.05) 
(figure 2). 
   3- The effect of Baclofen on the created pain 
in quiescent phase of formalin test in diabetes: 
injection of Baclofen before injection of 
formalin significantly reduces the created pain in 
quiescent phase in one week following diabetes 
(figure 3) (P<0.05). 
   In addition, in 4 weeks after diabetes, injection 
of Baclofen significantly (P<0.05) reduces the 








Figure 1. Formalin induced pain increases significantly in 











Figure 2. In phase 2, the effect of Baclofen analgesia on 










Figure 3. Baclofen significantly decreases the increased 
pain in the quiescent phase in diabetic rats 
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     This study shows that diabetes increased the 
formalin induced pain; insufficient studies about 
painful diabetic neuropathy prohibit its 
treatment. Anatomical studies couldn’t 
differentiate between painful diabetic 
neuropathy, so the treatment of such patients has 
limited the use of usual anti pain drugs.  It seems 
that the creation of experimental diabetes in 
rodents is a good way to test some drug effects 
in the lack of main neuropathy. 
     There are several methods to detect the pain 
in the lab animals [8]. We have applied the 
formalin method that Faster recommended as the 
point score in the damaged tissue [2]; in this 
method we can also recognize the target site of 
the anti pain drugs that work centrally or 
peripherally or both [22]. The formalin test is 
easier to perform, and a well validated model 
[20]. The formalin test has two major phases 
(acute and chronic) and a quiescent phase 
between them [19]. 
      In our research we studied the effect of 
diabetes on formalin induced pain and on the 
Baclofen analgesia. We also studied the effect of 
Baclofen on the created pain in quiescent phase. 
Baclofen is a potent GABA receptor agonist 
used in the treatment of trigeminal neuralgia 
[16]. Exogenic administration of GABA agonist 
reverses spinal nerve ligation-induced 
hyperalgesia [10].  In this research we found out 
that diabetes could increase pain in our model 
animals. There are several reasons that indicated 
the effect of diabetes on formalin induced pain. 
In hyperglycemic patients with STZ, protein 
kinas C is increased, that creates pain after 
mechanical stimulation.  Protein kinas C acts as 
intermediary to increase the ability of C fiber 
stimulation that in this painful neuropathy model 
creates pain [23]. The researchers indicated that 
in hyperglycemia, aldosreducats was the first 
enzyme produced in CNS and peripheral nerves 
and with the effect of tolerated (the enzyme’s 
inhibitor) the pain decrease [24]. 
     As we know pain stimulation reaches to the 
spinal cord, descending pain control systems and 
also some of the local mechanisms act on it; it 
then reaches to the thalamus and cortex. 
 Disease, inflammation and hurt to the nerve 
system create important changes in pain 
pathways such as stimulation, gene adjustment 
and will express new molecules such as 
neurotransmitter enzymes and receptors [12, 13]. 
An increased release of glutamate and activation 
of the NMDA [N-methyl-D-aspartate) receptor 
would maintain the hyperalgesia state. Data 
suggest that diabetes-induced hyperalgesia may 
be the consequence of increased excitatory tone 
within the spinal cord [11]. Also due to the fact 
that there is an increase in some metabolite such 
as sorbitol and Fructose in nerve and spinal cord 
in diabetic animals with STZ (streptozotocin) 
[24], the summation of these materials can be 
one of the factors in the creation of pain in 
diabetes. Thermal hyperalgesia showed a 
reduced sensitivity to the anti-nociceptive effect 
of Baclofen (4 mg/kg i.p.) [11]. 
     In this study diabetes increased pain in 
quiescent phase in addition of the first and 
second phases of formalin test. The 
pharmacological change of quiescent phase is 
unknown, it seems that, there is a network for 
decreasing pain in the quiescent phase, in the 
creation of this phase; both descending pain 
control system and endognic anti pain system 
are involved. Also it was indicated that the 
quiescent phase maybe because of inhibitory 
cabaergic system or endognic opiate system that 
with the effect of GABA antagonist or opiate 
antagonist, it creates a pain activity in this phase 
[13], so the creation of pain in quiescent phase 
indicated that in diabetes the endognic pain 
control system is inhibited and it seems that 
diabetes can inhibit or decrease the pain control 
system, and this indicated that diabetes is 
effective in both pain transmissions pathways 
and also the pain control systems. Another point 
is that it seems that diabetes could speed up the 
spinal cord activity in the responses to the main 
stimulation and the quiescent phase pain; 
moreover, it can be the reaction of second phase 
pain velocity. It means that diabetes can increase 
the velocity of inflammatory reaction, and so it 
speeded up the beginning of chronic pain. 
Previous studies indicated that in the 4 weeks 
after the beginning of diabetes, there is an 
increased pain in quiescent phase [24]. 
     In this study we indicated that the creation of 
the pain is before 4 weeks of the onset of 
diabetes (it begins from the first week). It is 
suggested in a short time of experimental 
diabetes, the content of substance in the 
peripheral nerves and the ganglion of the 
posterior roots of the spinal cord may be 
different. Therefore, it doesn’t seem in such 
short time of diabetic period, the axons 
degenerate.  Another subject in this study was 
the effect of diabetes on the Baclofen analgesia. 
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The former reports indicated that the 
hyperglycemia didn’t decrease AGF44 analgesia 
[23, 26] but it decreases morphine analgesia [7], 
so because of the different effects of the 
hyperglycemia on the anti pain drug effect, the 
effect of diabetes on the Baclofen analgesia as 
an anti pain drug was studied and indicated that 
hyperglycemia didn’t decrease the Baclofen 
analgesia, so it didn’t interfere with it. 
    Former studies indicated that the effect of an 
anti pain drug in the first phase of formalin test 
is because of the central effects and in the 
second phase it is because of the peripheral 
effects of drug [25]. Although researchers 
indicated that the effect of Baclofen in the 
treatment of central pain is more effective than 
peripheral pain such as diabetic painful 
neuropathy [7], the literature indicated that 
Baclofen in the first phase didn’t work as an anti 
pain drug, but in the second phase it was 
effective, so it might be that Baclofen in addition 
to its central effects has peripheral effects as 
well [5]. 
   This research indicated that in diabetes the 
Baclofen analgesic effect increased in the 
second phase, so we can say in hyperglycemia, 
Baclofen is effective in peripheral pain. In spite 
of the fact that indicated diabetes was not 
effective on Baclofen analgesia in first phase of 
formalin test (because of  increasing  pain in 
diabetic models), Baclofen decreased it, so the 
result of these two factors creates no difference 
in the first phase and this recommends that 
Baclofen in hyperglycemia has both central and 
peripheral effects. The inhibitory effects of both 
GABA and Baclofen were found to be 
significantly greater in trachea from control rats 
compared with tissues from diabetic rats [17]. 
The results of this study showed that diabetes 
didn’t decrease the Baclofen analgesic effect, so 
this drug can be useful as an anti pain drug in 
diabetes. 
     Moreover, it is useful for quieting increased 
pain in quiescent phase, as the third result of this 
study supported it. In a study Gomez and his 
colleagues demonstrate that Baclofen and other 
GABA drugs act the endocrine pancreas in vivo, 
ultimately increasing plasma insulin and 
decreasing high blood glucose levels of diabetic 
rats [9]. Many researchers suggest that Baclofen 
may be effective in delaying diabetes onset in 
mice by stimulating GABA activity, as this 
neurotransmitter, localized in the islets, may 
modulate insulin secretion and the antigen 
expression associated with it. 
Another point is that unlike morphine, 
diabetes didn’t have any interference with 
Baclofen analgesia, former study indicated that 
hyperglycemia decreased morphine analgesic 
effect, so because of the interference between 
hyperglycemia and morphine analgesia, and also 
because morphine, as an opiate drug creating 
tolerance and addiction, is not a perfect drug, 
this study suggested Baclofen as a non opiate 
drug for quieting diabetic pain. It seems that 
Gabaergic system is effective in creating the 
quiescent phase, that was weakened with 
diabetes, so in addition to the hyperglycemia 
effect and also creation of some difficulties in 
the opiate endogenic system for the increase of 
pain in quiescent phase, we have to pay more 
attention to another factor such as weakness of 
Gabaergic system with diabetes, that after 
injection of Baclofen as agonist of GABAB 
receptors, the increased pain in quiescent phase 
decreased, so this, supported the probability of 
Gabaergic system effect on the creation of the 
quiescent phase. 
   The dosage of Baclofen in this study was 10 
mg/kg; Baclofen with this dosage has an anti 
pain effect [5]. Although it was indicated that 
Baclofen analgesic effect works in a lower dose 
than it needs to create a disorder movement [12], 
due to the decrease in muscle activity in 
diabetes, and possibility of creating a disorder in 
their movement activity suggested that we have 
to pay more attention to the subject of the 
Baclofen resonance effect. The authors suggest 
more studies about the dosage of Baclofen. 
 
CONCLUSION 
   Diabetes creates a difference in transmission 
pathways and also in the pain control 
mechanisms, it can increase formalin induced 
pain that needs more study to understand the 
mechanism. 
     Diabetes creates an increased pain period that 
can be prevented with Baclofen and it can be 
used as a chronic pain model and be common 
with some of experimental pains in diabetes, and 
be suggested as a diabetic pain model. 
   The created pain in the quiescent phase in 
diabetes may also be the indication of the early 
second phase of pain in the formalin test.  
   Diabetes didn’t decrease the Baclofen 
analgesic effect, so Baclofen as an effective drug 
is useful for quieting the created pain in 
quiescent phase as a model of diabetic pain; 
therefore, in the treatment of the diabetic painful 
neuropathy Baclofen can be a drug of choice 
which needs more attention. 
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